BioNTech
BNTX
225 hedge funds and large institutions have $3.25B invested in BioNTech in 2021 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 71 increasing their positions, 47 reducing their positions, and 38 closing their positions.
84% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 38
83% more capital invested
Capital invested by funds: $1.77B → $3.25B (+$1.47B)
51% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 47
16% more funds holding
Funds holding: 194 → 225 (+31)
3.4% more ownership
Funds ownership: 9.13% → 12.53% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
23% less call options, than puts
Call options by funds: $301M | Put options by funds: $391M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$716M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$53.1M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$46M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$39M |
| 5 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$122M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$47.3M |
| 3 |
Jane Street
New York
|
-$20.9M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$19.9M |
BNTX Hedge Fund Activity: Q1 2021 in Review
225 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q1 2021, worth a combined $3.25B — up 83% from $1.77B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new BNTX positions and 38 closed out — a net gain of 32 holders — while 71 added to existing stakes and 47 trimmed.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $716M. The largest seller was Fidelity Investments, cutting an estimated $122M.
- 225 institutional investors held BioNTech (BNTX) as of Q1 2021, up from 194 in Q4 2020.
- Funds reported $3.25B of BioNTech stock for Q1 2021, up 83% quarter-over-quarter.
- 70 funds opened new BioNTech positions in Q1 2021 and 38 closed out, a net change of +32 holders.
- The largest BioNTech buyer in Q1 2021 was Baillie Gifford & Co, an estimated $716M added.
- The largest BioNTech seller in Q1 2021 was Fidelity Investments, an estimated $122M sold.
Based on aggregated 13F filings for Q1 2021.